REVOLUTION Medicines

Historical price data

Revolution Medicines is a clinical-stage biopharmaceutical company with a mission to develop targeted therapies for RAS-addicted cancers, one of the most prevalent and challenging oncogenic drivers. Its core achievement is the development of a proprietary tri-complex inhibitor platform that enables the direct targeting of active, GTP-bound 'RAS(ON)' proteins, a frontier long considered undruggable. The company's strategy is to advance a deep pipeline of RAS(ON) inhibitors through clinical development, aiming to establish a new standard of care. This scientific and strategic focus has garnered significant investor confidence, reflected in its substantial market valuation.

Proprietary Tri-Complex Inhibitor Platform that recruits the cellular chaperone cyclophilin A to create a novel interface for selectively inhibiting active-state 'RAS(ON)' proteins and other challenging targets.

Revolution faces direct competition from approved KRASG12C inhibitors (Amgen, Mirati/BMS) and a crowded field of companies developing therapies for non-G12C mutations, including Mirati/BMS, Johnson & Johnson, and several biotechs. Its primary competitive advantages are the first-in-class pan-RAS approach of RMC-6236 and the unique mechanism of its tri-complex platform.